People · Operator

Patrick I. Vink

Named in public records as an officer, director or promoter · active 2018–2018 · Pharmaceuticals

1
Companies
1
Filings
$228.0M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Concordia International Corp.PharmaceuticalsSeries D+$228.0M$8.1B2018
Operator network

Patrick I. Vink at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Itzhak Krinsky · 2 companies · 1 sharedItzhak KrinskyRandy Benson · 2 companies · 1 sharedRandy BensonAdeel I. Ahmad · 1 companies · 1 sharedAdeel I. AhmadDouglas Deeth · 1 companies · 1 sharedDouglas DeethFrancis I. Perier · 1 companies · 1 sharedFrancis I. PerierGraeme I. Duncan · 1 companies · 1 sharedGraeme I. DuncanGuy I. Clark · 1 companies · 1 sharedGuy I. ClarkJeridean I. Young · 1 companies · 1 sharedJeridean I. YoungKarl I. Belk · 1 companies · 1 sharedKarl I. BelkPaul I. Burden · 1 companies · 1 sharedPaul I. BurdenRobert I. Sully · 1 companies · 1 sharedRobert I. SullyRochelle Fuhrmann · 1 companies · 1 sharedRochelle FuhrmannSimon I. Tucker · 1 companies · 1 sharedSimon I. TuckerVikram I. Kamath · 1 companies · 1 sharedVikram I. KamathConcordia International Corp. · $228.0M raisedConcordia Internation…Patrick I. VinkPV
Patrick I. Vink Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Patrick I. Vink on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Itzhak Krinsky12
Randy Benson12
Jeridean I. Young11
Vikram I. Kamath11
Robert I. Sully11
Karl I. Belk11
Simon I. Tucker11
Guy I. Clark11
Francis I. Perier11
Rochelle Fuhrmann11
Adeel I. Ahmad11
Paul I. Burden11
Douglas Deeth11
Graeme I. Duncan11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.